Researchers at Tel Aviv University have created a laboratory model that closely mimics eosinophilic gastritis (EoG), a rare allergic condition of the stomach. The model allowed them to identify the immune pathways that drive the disease and understand why a new class of biologic drugs currently in clinical trials may offer relief for patients.

Eosinophilic gastritis is a chronic inflammatory disorder marked by the buildup of eosinophils, a type of white blood cell, in the stomach lining. People with EoG often experience abdominal pain, nausea, vomiting, and difficulty eating. Until now, studying the disease has been hampered by the lack of a reliable animal model, leaving many questions about its underlying causes unanswered.

Key Takeaways

  • Eosinophilic gastritis is a rare allergic stomach disease with limited treatment options.
  • Tel Aviv University researchers developed a faithful experimental model of EoG.
  • The model revealed specific immune pathways responsible for the disease.
  • Findings explain how new biologic therapies might target those pathways.

What Is Eosinophilic Gastritis?

Eosinophilic gastritis belongs to a group of eosinophilic gastrointestinal disorders (EGIDs). In these conditions, eosinophils accumulate in the digestive tract and trigger inflammation. Common triggers include certain foods, environmental allergens, and genetic predispositions. Symptoms can overlap with other stomach problems, which often delays diagnosis. Current treatments rely on steroids and dietary changes, but these do not work for everyone and can have side effects.

The disease is considered rare, but its recognition has grown in recent years. Researchers believe that better understanding of the immune mechanisms behind EoG could lead to more targeted therapies and reduce the need for broad immunosuppression.

The New Experimental Model

The Tel Aviv University team created one of the first experimental models that faithfully reproduces the key features of human eosinophilic gastritis. According to the original report on Medical Xpress, the model was essential for observing how the disease develops from start to finish. Before this, scientists had to rely on indirect observations or limited human tissue samples.

By using the model, the researchers could track immune cell activity in the stomach over time. They also tested how different triggers affected the severity of inflammation. This allowed them to pinpoint the specific immune pathways that are activated during EoG and separate them from pathways involved in other allergic conditions.

Key Immune Pathways Identified

The team identified that a particular subset of immune cells, known as type 2 helper T cells (Th2 cells), plays a central role in driving eosinophil accumulation in the stomach. These cells release signaling molecules called cytokines, such as interleukin-5 (IL-5) and interleukin-13 (IL-13), which attract eosinophils and keep them alive in the tissue.

Additionally, the researchers found that the stomach lining in EoG produces elevated levels of a protein called eotaxin, which is a powerful chemoattractant for eosinophils. Blocking the interaction between eotaxin and its receptor on eosinophils reduced inflammation in the model. These findings align with what has been observed in patients with other eosinophilic diseases, such as eosinophilic esophagitis, but the specific tissue environment of the stomach appears to influence the response.

Implications for Biologic Therapies

Several biologic therapies that target IL-5, IL-13, or the eotaxin receptor are currently being tested in clinical trials for eosinophilic gastrointestinal disorders. The new model provides a mechanistic explanation for why these drugs may be effective in EoG. By neutralizing the specific cytokines that drive eosinophil recruitment and survival, these biologics could reduce stomach inflammation without suppressing the entire immune system.

The study also suggests that patient responses to these therapies may vary depending on which immune pathway is dominant in each individual. The model could be used in the future to screen potential drugs and personalize treatment strategies for people with EoG.

Future Directions

The Tel Aviv University team plans to refine their model further, including testing the effects of food allergens and examining how the disease interacts with the gut microbiome. They also hope to collaborate with clinicians to validate the pathways they identified in human patients. The ultimate goal is to translate these findings into new diagnostic tools and treatments that improve the quality of life for people with this rare allergic stomach disease.

Frequently Asked Questions

What is eosinophilic gastritis?

Eosinophilic gastritis is a rare allergic condition in which high numbers of eosinophils, a type of white blood cell, accumulate in the lining of the stomach. This causes inflammation and symptoms such as abdominal pain, nausea, vomiting, bloating, and early satiety. It is often triggered by food allergens and can be difficult to diagnose because its symptoms mimic other digestive disorders.

How is the new model different from previous ones?

Previous models of eosinophilic gastritis did not fully capture the chronic inflammation and immune cell activity seen in humans. The Tel Aviv University model more faithfully reproduces the disease, allowing researchers to track the accumulation of eosinophils over time and test how specific immune pathways contribute to the condition. This makes it a more reliable tool for studying mechanisms and potential treatments.

What are biologic therapies for eosinophilic gastritis?

Biologic therapies are drugs that target specific molecules in the immune system. For eosinophilic gastritis, the most promising biologics block cytokines such as interleukin-5 or interleukin-13, or they block the eotaxin receptor on eosinophils. These drugs are designed to reduce eosinophil recruitment and survival in the stomach lining, potentially offering a more targeted treatment option. Several are currently under investigation in clinical trials.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.